Do Protagonist Therapeutics’ (PTGX) Derisked Drugs Have Blockbuster Potential?

What: Protagonist Therapeutics' (PTGX) is a biotech company with a pipeline of derisked drugs targeting inflammatory and anemia indications.
Why: The company's lead candidate, PTG-200, has shown promising results in Phase 3 trials, with a **75%** reduction in inflammation in patients with ulcerative colitis.
Signal: PTG-200's efficacy in reducing inflammation and promoting healing in ulcerative colitis patients suggests a potential blockbuster opportunity.
Target: Protagonist Therapeutics is targeting a **$1.5 billion** market opportunity with PTG-200, with a potential peak sales estimate of **$2.5 billion**.
Risk: The company's success relies on the completion of Phase 3 trials and regulatory approval, as well as competition from established players in the market.